Heparin therapy and thromboprophylaxis with heparin for individuals with infection and medical inpatients in general remains controversial [7,8]. Previous studies on thromboprophylaxis with low-molecular-weight heparin (LMWH) have found limited effect on clinically relevant outcomes in hospitalized medical patients with a number-needed-to-treat of approximately 250 to prevent symptomatic pulmonary embolism and a similar number-needed-to-harm in the form of major bleeding, resulting in little or no net benefit [7]. Moreover, thromboprophylaxis with LMWH has never been shown to prevent death in hospitalized medical patients including those with severe infection [9]. Prolonged thromboprophylaxis has been considered of potential benefit, but AC extended beyond hospital discharge for medical illness was not found to have an effect on risk for symptomatic VTE or death [10].